You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

SUNItinib

( soo-NIT-in-ib )
Funding:
Exceptional Access Program
  • SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria
  • SUNItinib - Metastatic renal cell carcinoma, with specific criteria
  • SUNItinib - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumours (pNET), according to specific criteria
Other Name(s): Sutent®
Appearance: capsule In various strengths and colours

Patient Info Sheet

May 2018

What it is used for

• For treating some types of kidney cancer, as well as gastrointestinal stromal tumors (GIST) - a rare cancer usually affecting the stomach or intestines, and a rare type of pancreas cancer.



You might also be interested in